With IPOs not an option, should pharma feed the biotech ecosystem?

This year's J.P. Morgan Healthcare Conference had its share of bright new ideas and pioneering technologies, tempered by the simple reality that key financial trends on tap for 2012 have already been playing out for several tough years. Report

Suggested Articles

An online pharmacy has again criticized FDA action after tipping off regulators to the existence of a dangerous impurity in Zantac and other antacids.

A group of senators is asking the FTC to take a careful look at pharma mergers given the cost of drugs in the U.S.

Life’s been tough for J&J's prostate cancer med Erleada in its battle with Pfizer-Astellas’ Xtandi. A new FDA nod could help level the playing field.…